<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33831358</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>06</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1097-4164</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>81</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jun</Month>
              <Day>03</Day>
            </PubDate>
          </JournalIssue>
          <Title>Molecular cell</Title>
          <ISOAbbreviation>Mol Cell</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Immune-regulated IDO1-dependent tryptophan metabolism is source of one-carbon units for pancreatic cancer and stellate cells.</ArticleTitle>
        <Pagination>
          <StartPage>2290</StartPage>
          <EndPage>2302.e7</EndPage>
          <MedlinePgn>2290-2302.e7</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.molcel.2021.03.019</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1097-2765(21)00214-8</ELocationID>
        <Abstract>
          <AbstractText>Cancer cells adapt their metabolism to support elevated energetic and anabolic demands of proliferation. Folate-dependent one-carbon metabolism is a critical metabolic process underpinning cellular proliferation supplying carbons for the synthesis of nucleotides incorporated into DNA and RNA. Recent research has focused on the nutrients that supply one-carbons to the folate cycle, particularly serine. Tryptophan is a theoretical source of one-carbon units through metabolism by IDO1, an enzyme intensively investigated in the context of tumor immune evasion. Using in vitro and in vivo pancreatic cancer models, we show that IDO1 expression is highly context dependent, influenced by attachment-independent growth and the canonical activator IFNγ. In IDO1-expressing cancer cells, tryptophan is a bona fide one-carbon donor for purine nucleotide synthesis in vitro and in vivo. Furthermore, we show that cancer cells release tryptophan-derived formate, which can be used by pancreatic stellate cells to support purine nucleotide synthesis.</AbstractText>
          <CopyrightInformation>Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Newman</LastName>
            <ForeName>Alice Clare</ForeName>
            <Initials>AC</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Switchback Road, Glasgow G61 1QH, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Falcone</LastName>
            <ForeName>Mattia</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Switchback Road, Glasgow G61 1QH, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huerta Uribe</LastName>
            <ForeName>Alejandro</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Switchback Road, Glasgow G61 1QH, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Tong</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Switchback Road, Glasgow G61 1QH, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Athineos</LastName>
            <ForeName>Dimitris</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Research UK Beatson Institute, Switchback Road, Glasgow G61 1BD, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pietzke</LastName>
            <ForeName>Matthias</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Research UK Beatson Institute, Switchback Road, Glasgow G61 1BD, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vazquez</LastName>
            <ForeName>Alexei</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Switchback Road, Glasgow G61 1QH, UK; Cancer Research UK Beatson Institute, Switchback Road, Glasgow G61 1BD, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Blyth</LastName>
            <ForeName>Karen</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Switchback Road, Glasgow G61 1QH, UK; Cancer Research UK Beatson Institute, Switchback Road, Glasgow G61 1BD, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Maddocks</LastName>
            <ForeName>Oliver David Kenneth</ForeName>
            <Initials>ODK</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Switchback Road, Glasgow G61 1QH, UK. Electronic address: oliver.maddocks@glasgow.ac.uk.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>C53309/A19702</GrantID>
            <Acronym>CRUK_</Acronym>
            <Agency>Cancer Research UK</Agency>
            <Country>United Kingdom</Country>
          </Grant>
          <Grant>
            <GrantID>A17196</GrantID>
            <Acronym>CRUK_</Acronym>
            <Agency>Cancer Research UK</Agency>
            <Country>United Kingdom</Country>
          </Grant>
          <Grant>
            <GrantID>A29799</GrantID>
            <Acronym>CRUK_</Acronym>
            <Agency>Cancer Research UK</Agency>
            <Country>United Kingdom</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>04</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Mol Cell</MedlineTA>
        <NlmUniqueID>9802571</NlmUniqueID>
        <ISSNLinking>1097-2765</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005561">Formates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C576710">IDO1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C583637">IDO1 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D050503">Indoleamine-Pyrrole 2,3,-Dioxygenase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010091">Oximes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000628667">Trp53 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0YIW783RG1</RegistryNumber>
          <NameOfSubstance UI="C030544">formic acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>452VLY9402</RegistryNumber>
          <NameOfSubstance UI="D012694">Serine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>71596A9R13</RegistryNumber>
          <NameOfSubstance UI="C000613752">epacadostat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>7440-44-0</RegistryNumber>
          <NameOfSubstance UI="D002244">Carbon</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>82115-62-6</RegistryNumber>
          <NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8DUH1N11BX</RegistryNumber>
          <NameOfSubstance UI="D014364">Tryptophan</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.5.2</RegistryNumber>
          <NameOfSubstance UI="C495971">Hras protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.5.2</RegistryNumber>
          <NameOfSubstance UI="D016283">Proto-Oncogene Proteins p21(ras)</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D064591" MajorTopicYN="N">Allografts</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002244" MajorTopicYN="N">Carbon</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D021441" MajorTopicYN="N">Carcinoma, Pancreatic Ductal</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005561" MajorTopicYN="N">Formates</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050503" MajorTopicYN="N">Indoleamine-Pyrrole 2,3,-Dioxygenase</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053858" MajorTopicYN="N">Metabolic Networks and Pathways</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010091" MajorTopicYN="N">Oximes</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010190" MajorTopicYN="N">Pancreatic Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058954" MajorTopicYN="N">Pancreatic Stellate Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016283" MajorTopicYN="N">Proto-Oncogene Proteins p21(ras)</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012694" MajorTopicYN="N">Serine</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014364" MajorTopicYN="N">Tryptophan</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019139" MajorTopicYN="N">Tumor Escape</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016159" MajorTopicYN="N">Tumor Suppressor Protein p53</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">IDO1</Keyword>
        <Keyword MajorTopicYN="Y">IFNγ</Keyword>
        <Keyword MajorTopicYN="Y">PDAC</Keyword>
        <Keyword MajorTopicYN="Y">cancer immunology</Keyword>
        <Keyword MajorTopicYN="Y">cancer metabolism</Keyword>
        <Keyword MajorTopicYN="Y">epacadostat</Keyword>
        <Keyword MajorTopicYN="Y">formate</Keyword>
        <Keyword MajorTopicYN="Y">immunometabolism</Keyword>
        <Keyword MajorTopicYN="Y">immunotherapy</Keyword>
        <Keyword MajorTopicYN="Y">one-carbon metabolism</Keyword>
        <Keyword MajorTopicYN="Y">pancreas</Keyword>
        <Keyword MajorTopicYN="Y">serine</Keyword>
        <Keyword MajorTopicYN="Y">stellate cells</Keyword>
        <Keyword MajorTopicYN="Y">tryptophan</Keyword>
        <Keyword MajorTopicYN="Y">tumor microenvironment</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of interests O.D.K.M. contributed to CRUK Cancer Research Technology filing of UK patent application no. 1609441.9, relating to dietary modulation of amino acids, and is a co-founder, shareholder, and advisor of Faeth Therapeutics. The other authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>8</Day>
          <Hour>20</Hour>
          <Minute>15</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33831358</ArticleId>
        <ArticleId IdType="pmc">PMC8189438</ArticleId>
        <ArticleId IdType="doi">10.1016/j.molcel.2021.03.019</ArticleId>
        <ArticleId IdType="pii">S1097-2765(21)00214-8</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Auciello F.R., Bulusu V., Oon C., Tait-Mulder J., Berry M., Bhattacharyya S., Tumanov S., Allen-Petersen B.L., Link J., Kendsersky N.D. A Stromal Lysolipid-Autotaxin Signaling Axis Promotes Pancreatic Tumor Progression. Cancer Discov. 2019;9:617–627.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6497553</ArticleId>
            <ArticleId IdType="pubmed">30837243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baksh S.C., Todorova P.K., Gur-Cohen S., Hurwitz B., Ge Y., Novak J.S.S., Tierney M.T., Dela Cruz-Racelis J., Fuchs E., Finley L.W.S. Extracellular serine controls epidermal stem cell fate and tumour initiation. Nat. Cell Biol. 2020;22:779–790.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7343604</ArticleId>
            <ArticleId IdType="pubmed">32451440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burgos-Barragan G., Wit N., Meiser J., Dingler F.A., Pietzke M., Mulderrig L., Pontel L.B., Rosado I.V., Brewer T.F., Cordell R.L. Mammals divert endogenous genotoxic formaldehyde into one-carbon metabolism. Nature. 2017;548:549–554.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5714256</ArticleId>
            <ArticleId IdType="pubmed">28813411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ducker G.S., Chen L., Morscher R.J., Ghergurovich J.M., Esposito M., Teng X., Kang Y., Rabinowitz J.D. Reversal of Cytosolic One-Carbon Flux Compensates for Loss of the Mitochondrial Folate Pathway. Cell Metab. 2016;23:1140–1153.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4909566</ArticleId>
            <ArticleId IdType="pubmed">27211901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao Y., Yang W., Pan M., Scully E., Girardi M., Augenlicht L.H., Craft J., Yin Z. Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J. Exp. Med. 2003;198:433–442.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2194096</ArticleId>
            <ArticleId IdType="pubmed">12900519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garber K. A new cancer immunotherapy suffers a setback. Science. 2018;360:588.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29748264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamilton T.G., Klinghoffer R.A., Corrin P.D., Soriano P. Evolutionary divergence of platelet-derived growth factor alpha receptor signaling mechanisms. Mol. Cell. Biol. 2003;23:4013–4025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC155222</ArticleId>
            <ArticleId IdType="pubmed">12748302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21376230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hennequart M., Pilotte L., Cane S., Hoffmann D., Stroobant V., Plaen E., Van den Eynde B.J. Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance. Cancer Immunol. Res. 2017;5:695–709.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28765120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hingorani S.R., Wang L., Multani A.S., Combs C., Deramaudt T.B., Hruban R.H., Rustgi A.K., Chang S., Tuveson D.A. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005;7:469–483.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15894267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hornyák L., Dobos N., Koncz G., Karányi Z., Páll D., Szabó Z., Halmos G., Székvölgyi L. The Role of Indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy. Front. Immunol. 2018;9:151.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5797779</ArticleId>
            <ArticleId IdType="pubmed">29445380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science. 2012;336:1040–1044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3526189</ArticleId>
            <ArticleId IdType="pubmed">22628656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kanarek N., Keys H.R., Cantor J.R., Lewis C.A., Chan S.H., Kunchok T., Abu-Remaileh M., Freinkman E., Schweitzer L.D., Sabatini D.M. Histidine catabolism is a major determinant of methotrexate sensitivity. Nature. 2018;559:632–636.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6082631</ArticleId>
            <ArticleId IdType="pubmed">29995852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katz J.B., Muller A.J., Prendergast G.C. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol. Rev. 2008;222:206–221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18364004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim D., Fiske B.P., Birsoy K., Freinkman E., Kami K., Possemato R.L., Chudnovsky Y., Pacold M.E., Chen W.W., Cantor J.R. SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance. Nature. 2015;520:363–367.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4533874</ArticleId>
            <ArticleId IdType="pubmed">25855294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Labuschagne C.F., van den Broek N.J., Mackay G.M., Vousden K.H., Maddocks O.D. Serine, but not glycine, supports one-carbon metabolism and proliferation of cancer cells. Cell Rep. 2014;7:1248–1258.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24813884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>LeBoeuf S.E., Wu W.L., Karakousi T.R., Karadal B., Jackson S.R., Davidson S.M., Wong K.K., Koralov S.B., Sayin V.I., Papagiannakopoulos T. Activation of Oxidative Stress Response in Cancer Generates a Druggable Dependency on Exogenous Non-essential Amino Acids. Cell Metab. 2020;31:339–350.e4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7004873</ArticleId>
            <ArticleId IdType="pubmed">31813821</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Litzenburger U.M., Opitz C.A., Sahm F., Rauschenbach K.J., Trump S., Winter M., Ott M., Ochs K., Lutz C., Liu X. Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR. Oncotarget. 2014;5:1038–1051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4011581</ArticleId>
            <ArticleId IdType="pubmed">24657910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu X., Shin N., Koblish H.K., Yang G., Wang Q., Wang K., Leffet L., Hansbury M.J., Thomas B., Rupar M. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood. 2010;115:3520–3530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20197554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Locasale J.W., Grassian A.R., Melman T., Lyssiotis C.A., Mattaini K.R., Bass A.J., Heffron G., Metallo C.M., Muranen T., Sharfi H. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat. Genet. 2011;43:869–874.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3677549</ArticleId>
            <ArticleId IdType="pubmed">21804546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maddocks O.D., Berkers C.R., Mason S.M., Zheng L., Blyth K., Gottlieb E., Vousden K.H. Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature. 2013;493:542–546.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6485472</ArticleId>
            <ArticleId IdType="pubmed">23242140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maddocks O.D.K., Athineos D., Cheung E.C., Lee P., Zhang T., van den Broek N.J.F., Mackay G.M., Labuschagne C.F., Gay D., Kruiswijk F. Modulating the therapeutic response of tumours to dietary serine and glycine starvation. Nature. 2017;544:372–376.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28425994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meiser J., Tumanov S., Maddocks O., Labuschagne C.F., Athineos D., Van Den Broek N., Mackay G.M., Gottlieb E., Blyth K., Vousden K. Serine one-carbon catabolism with formate overflow. Sci. Adv. 2016;2:e1601273.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5091358</ArticleId>
            <ArticleId IdType="pubmed">27819051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meiser J., Schuster A., Pietzke M., Vande Voorde J., Athineos D., Oizel K., Burgos-Barragan G., Wit N., Dhayade S., Morton J.P. Increased formate overflow is a hallmark of oxidative cancer. Nat. Commun. 2018;9:1368.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5893600</ArticleId>
            <ArticleId IdType="pubmed">29636461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mezrich J.D., Fechner J.H., Zhang X., Johnson B.P., Burlingham W.J., Bradfield C.A. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J. Immunol. 2010;185:3190–3198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2952546</ArticleId>
            <ArticleId IdType="pubmed">20720200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mojic M., Takeda K., Hayakawa Y. The Dark Side of IFN-γ: Its Role in Promoting Cancer Immunoevasion. Int. J. Mol. Sci. 2017;19:89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5796039</ArticleId>
            <ArticleId IdType="pubmed">29283429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morton J.P., Timpson P., Karim S.A., Ridgway R.A., Athineos D., Doyle B., Jamieson N.B., Oien K.A., Lowy A.M., Brunton V.G. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc. Natl. Acad. Sci. USA. 2010;107:246–251.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2806749</ArticleId>
            <ArticleId IdType="pubmed">20018721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Munn D.H., Sharma M.D., Baban B., Harding H.P., Zhang Y., Ron D., Mellor A.L. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity. 2005;22:633–642.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15894280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murphy M.P. How mitochondria produce reactive oxygen species. Biochem. J. 2009;417:1–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2605959</ArticleId>
            <ArticleId IdType="pubmed">19061483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muthusamy T., Cordes T., Handzlik M.K., You L., Lim E.W., Gengatharan J., Pinto A.F.M., Badur M.G., Kolar M.J., Wallace M. Serine restriction alters sphingolipid diversity to constrain tumour growth. Nature. 2020;586:790–795.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7606299</ArticleId>
            <ArticleId IdType="pubmed">32788725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newman A.C., Maddocks O.D.K. One-carbon metabolism in cancer. Br. J. Cancer. 2017;116:1499–1504.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5518849</ArticleId>
            <ArticleId IdType="pubmed">28472819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newman A.C., Maddocks O.D.K. Serine and Functional Metabolites in Cancer. Trends Cell Biol. 2017;27:645–657.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28601431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pacold M.E., Brimacombe K.R., Chan S.H., Rohde J.M., Lewis C.A., Swier L.J., Possemato R., Chen W.W., Sullivan L.B., Fiske B.P. A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate. Nat. Chem. Biol. 2016;12:452–458.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4871733</ArticleId>
            <ArticleId IdType="pubmed">27110680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Possemato R., Marks K.M., Shaul Y.D., Pacold M.E., Kim D., Birsoy K., Sethumadhavan S., Woo H.K., Jang H.G., Jha A.K. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature. 2011;476:346–350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3353325</ArticleId>
            <ArticleId IdType="pubmed">21760589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prendergast G.C. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene. 2008;27:3889–3900.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18317452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shaul Y.D., Yuan B., Thiru P., Nutter-Upham A., McCallum S., Lanzkron C., Bell G.W., Sabatini D.M. MERAV: a tool for comparing gene expression across human tissues and cell types. Nucleic Acids Res. 2016;44(D1):D560–D566.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4702927</ArticleId>
            <ArticleId IdType="pubmed">26626150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sonner J.K., Deumelandt K., Ott M., Thomé C.M., Rauschenbach K.J., Schulz S., Munteanu B., Mohapatra S., Adam I., Hofer A.C. The stress kinase GCN2 does not mediate suppression of antitumor T cell responses by tryptophan catabolism in experimental melanomas. OncoImmunology. 2016;5:e1240858.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5214097</ArticleId>
            <ArticleId IdType="pubmed">28123877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sousa C.M., Biancur D.E., Wang X., Halbrook C.J., Sherman M.H., Zhang L., Kremer D., Hwang R.F., Witkiewicz A.K., Ying H. Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. Nature. 2016;536:479–483.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5228623</ArticleId>
            <ArticleId IdType="pubmed">27509858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sullivan M.R., Danai L.V., Lewis C.A., Chan S.H., Gui D.Y., Kunchok T., Dennstedt E.A., Vander Heiden M.G., Muir A. Quantification of microenvironmental metabolites in murine cancers reveals determinants of tumor nutrient availability. eLife. 2019;8:e44235.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6510537</ArticleId>
            <ArticleId IdType="pubmed">30990168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sullivan M.R., Mattaini K.R., Dennstedt E.A., Nguyen A.A., Sivanand S., Reilly M.F., Meeth K., Muir A., Darnell A.M., Bosenberg M.W. Increased Serine Synthesis Provides an Advantage for Tumors Arising in Tissues Where Serine Levels Are Limiting. Cell Metab. 2019;29:1410–1421.e4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6551255</ArticleId>
            <ArticleId IdType="pubmed">30905671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun Y., Chin Y.E., Weisiger E., Malter C., Tawara I., Toubai T., Gatza E., Mascagni P., Dinarello C.A., Reddy P. Cutting edge: negative regulation of dendritic cells through acetylation of the nonhistone protein STAT-3. J. Immunol. 2009;182:5899–5903.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6232841</ArticleId>
            <ArticleId IdType="pubmed">19414739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Terness P., Bauer T.M., Röse L., Dufter C., Watzlik A., Simon H., Opelz G. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J. Exp. Med. 2002;196:447–457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2196057</ArticleId>
            <ArticleId IdType="pubmed">12186837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu C., Sui S., Shang Y., Yu Z., Han J., Zhang G., Ntim M., Hu M., Gong P., Chen H., Zhang X. The landscape of immune cell infiltration and its clinical implications of pancreatic ductal adenocarcinoma. J. Adv. Res. 2020;24:139–148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7171261</ArticleId>
            <ArticleId IdType="pubmed">32322419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu J., Wang Y., Yan F., Zhang P., Li H., Zhao H., Yan C., Yan F., Ren X. Noncanonical NF-κB activation mediates STAT3-stimulated IDO upregulation in myeloid-derived suppressor cells in breast cancer. J. Immunol. 2014;193:2574–2586.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4719564</ArticleId>
            <ArticleId IdType="pubmed">25063873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu C.P., Fu S.F., Chen X., Ye J., Ye Y., Kong L.D., Zhu Z. The Clinicopathological and Prognostic Significance of IDO1 Expression in Human Solid Tumors: Evidence from a Systematic Review and Meta-Analysis. Cell. Physiol. Biochem. 2018;49:134–143.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30134237</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
